

PHARMACY POLICY STATEMENT

Common Ground Healthcare Cooperative (CGHC)

DRUG NAME	Doptelet (avatrombopag)
BENEFIT TYPE	Pharmacy
STATUS	Prior Authorization Required

Doptelet, approved by the FDA in 2018, is a small molecule thrombopoietin (TPO) receptor agonist indicated for the treatment of thrombocytopenia in adults with chronic liver disease (CLD) who are scheduled to undergo a procedure, and for adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. TPO is important for regulating thrombopoiesis. The agonistic effect of Doptelet upregulates the production of platelets. TPO receptor agonists (TPO-RA) have been associated with thrombotic and thromboembolic complications. Doptelet should not be administered in an attempt to normalize platelet counts. Doptelet was the first TPO receptor agonist approved for the indicated CLD population.

Thrombocytopenia is a condition of low platelet counts. It is the most common hematologic complication in patients with CLD, and 1% experience severe thrombocytopenia (platelet count <50,000/ μ L). Advanced disease often requires numerous medical and/or surgical diagnostic and therapeutic procedures. Thrombocytopenia may be associated with increased bleeding risk in these invasive procedures.

Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by low levels of platelets. ITP duration of less than 3 months is referred to as newly diagnosed, 3-12 months as persistent, and greater than 12 months is considered chronic.

Doptelet (avatrombopag) will be considered for coverage when the following criteria are met:

Thrombocytopenia with chronic liver disease (CLD)

For **initial** authorization:

1. Member is at least 18 years of age; AND
2. Medication must be prescribed by or in consultation with a hematologist, hepatologist, or gastroenterologist; AND
3. Member has a documented diagnosis of chronic liver disease (CLD); AND
4. Member has a diagnosis of severe thrombocytopenia with a platelet count is < 50 x10⁹/L within the last 30 days; AND
5. Member is scheduled to undergo an invasive procedure; AND
6. Member does NOT have any of the following:
 - a) Thrombosis or prothrombotic condition
 - b) Liver transplant
7. Doptelet will not be used in combination with another TPO receptor agonist (such as Mulpleta).
8. **Dosage allowed/Quantity limit:** Begin 10-13 days prior to procedure; undergo procedure 5-8 days after last dose.
Platelet count less than 40 x10⁹/L: 60 mg (3 tablets) once daily for 5 days

Platelet count 40 to less than 50 x10⁹/L: 40 mg (2 tablets) once daily for 5 days.
QL: 15 tablets

If all the above requirements are met, the medication will be approved for 1 month.

For **reauthorization**:

1. Doptelet will not be reauthorized for continuous use.

Chronic Immune Thrombocytopenia (ITP)

For **initial** authorization:

1. Member is at least 18 years of age; AND
2. Medication must be prescribed by or in consultation with a hematologist; AND
3. Member has a documented diagnosis of chronic ITP of at least 6 months duration; AND
4. Member has had an insufficient response with at least one of the following treatments:
 - a) Corticosteroids (i.e., prednisone, prednisolone, methylprednisolone, dexamethasone)
 - b) Immunoglobulins
 - c) Splenectomy; AND
5. Member meets one of the following:
 - a) Current platelet count is < 30 x10⁹/L
 - b) 30 x10⁹/L to < 50 x10⁹/L with one of the following:
 - i) Active symptomatic bleeding other than minor mucocutaneous bleeding
 - ii) High risk factor for bleeding (i.e., on an anticoagulant, of older age (>60 years), other clearly identified comorbidity); AND
6. Member does NOT have secondary immune thrombocytopenia (i.e., non-idiopathic, due to another condition).
7. **Dosage allowed/Quantity limit:** Start at 20 mg (1 tablet) once daily. Adjust the dose or frequency of dosing to maintain platelet count greater than or equal to 50 x10⁹/L, per tables in prescribing information. Do not exceed 40 mg per day.
QL: 60 tablets per 30 days

Note: Discontinue if the platelet count does not increase to at least 50 x 10⁹/L after 4 weeks at the maximum dose of 40 mg once daily. Discontinue if the platelet count is greater than 400 x10⁹/L after 2 weeks of dosing at 20 mg once weekly.

If all the above requirements are met, the medication will be approved for 6 months.

For **reauthorization**:

1. Chart notes include documentation of achieving and maintaining a platelet count of at least 50 x 10⁹/L; AND
2. Member's platelet count is less than 200 x 10⁹/L or there is a plan to decrease the dose per prescribing information.

If all the above requirements are met, the medication will be approved for an additional 12 months.

CareSource considers Doptelet (avatrombopag) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

DATE	ACTION/DESCRIPTION
05/06/2019	New policy for Doptelet created.
07/24/2019	New indication of Immune thrombocytopenia (ITP) added. Status changed to preferred.
01/23/2023	Transferred to new template. Updated and added references. CLD: Added hepatology and GI as accepted specialists. Specified platelet lab must be within past 30 days. Shortened list of exclusions. Added not to be used in combination with another TPO-RA. ITP: Specified duration of chronic disease as at least 6 months. Removed “Other medications: cyclosporine A, mycophenolate mofetil, azathioprine, danazol, cyclophosphamide and/or rituximab” from list of accepted trials; none of these are initial/first line options per guidelines. Edited criteria under PC of 30,000-50,000. Added exclusion for secondary ITP. Reduced initial approval duration from 12 months to 6 months. For renewal, specified platelet improvement as 50,000 per drug label. For renewal added “or plan to decrease dose” to criterion for 200,000 ceiling PC.

References:

1. Doptelet [prescribing information]. AkaRx, Inc.; 2021.
2. Terrault N, Chen YC, Izumi N, et al. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. *Gastroenterology*. 2018;155(3):705-718. doi:10.1053/j.gastro.2018.05.025.
3. Poordad F, Terrault NA, Alkhouri N, Tian W, Allen LF, Rabinovitz M. Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies. *Int J Hepatol*. 2020;2020:5421632. Published 2020 Jan 25. doi:10.1155/2020/5421632
4. Hayashi H, Beppu T, Shirabe K, Maehara Y, Baba H. Management of thrombocytopenia due to liver cirrhosis: a review. *World J Gastroenterol*. 2014;20(10):2595-2605. doi:10.3748/wjg.v20.i10.2595
5. Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. *Liver Int*. 2017;37(6):778-793. doi:10.1111/liv.13317
6. Lim HI, Cuker A. Thrombocytopenia and liver disease: pathophysiology and periprocedural management. *Hematology Am Soc Hematol Educ Program*. 2022;2022(1):296-302. doi:10.1182/hematology.2022000408
7. Miller JB, Figueroa EJ, Haug RM, Shah NL. Thrombocytopenia in Chronic Liver Disease and the Role of Thrombopoietin Agonists. *Gastroenterol Hepatol (N Y)*. 2019;15(6):326-332.
8. Flisiak R, Antonov K, Drastich P, et al. Practice Guidelines of the Central European Hepatologic Collaboration (CEHC) on the Use of Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease Undergoing Invasive Procedures. *J Clin Med*. 2021;10(22):5419. Published 2021 Nov 19. doi:10.3390/jcm10225419
9. Markham A. Avatrombopag: A Review in Thrombocytopenia [published correction appears in *Drugs*. 2021 Dec;81(18):2169]. *Drugs*. 2021;81(16):1905-1913. doi:10.1007/s40265-021-01613-y
10. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. *Br J Haematol*. 2018;183(3):479-490. doi:10.1111/bjh.15573
11. Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. *Blood*. 2014;123(25):3887-3894. doi:10.1182/blood-2013-07-514398
12. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia [published correction appears in *Blood Adv*. 2020 Jan 28;4(2):252]. *Blood Adv*. 2019;3(23):3829-3866. doi:10.1182/bloodadvances.2019000966
13. Wojciechowski P, Wilson K, Nazir J, et al. Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis. *Adv Ther*. 2021;38(6):3113-3128. doi:10.1007/s12325-021-01752-4
14. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. *Blood Adv*. 2019;3(22):3780-3817. doi:10.1182/bloodadvances.2019000812

15. Song F, Al-Samkari H. Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice. *J Blood Med.* 2021;12:653-664. Published 2021 Jul 26. doi:10.2147/JBM.S259101

Effective date: 01/01/2025

Revised date: 01/23/2023